BREAKING NEWS
SC questions ED on timing of Kejriwal’s arrest ahead of LS polls, seeks its reply
Revanna case: BJP launches counter-attack on Congress, questions delayed action by Karnataka govt
SC questions ED on timing of Kejriwal’s arrest, seeks its reply
We don’t send dossiers on terror; ‘Bharat ghar mein ghus ke marta hai’: PM Modi
Cricket: India’s T20 World Cup squad announced
Nifty hits all-time high; Sensex nears lifetime peak
International students in Canada will be allowed to work only 24 hours a week from September
Suniel Shetty teases new project, says can’t wait to get back into ‘action’
Will push for full might of law against accused: BJP on Revanna case
JD(S) suspends Prajwal Revanna from party
Chilled beer sales rise in hot weather in Karnataka
This IPL is different, need to mentally accept challenge: KKR’s Varun Chakravarthy
Why has PM ignored plight of Marathwada’s farmers: Cong jabs Modi
Unwarranted, unsubstantiated imputations: MEA on Washington Post report on Pannun case
T20 World Cup: National selectors to meet in Ahmedabad today
Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity
PTI, Aug 24, 2021, 1:34 PM IST
New Delhi: Drug firm Zydus Cadila on Monday said it has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market. The company said it has received approval from the US Food and Drug Administration (USFDA) for the drug in 11 mg and 22 mg strengths.
Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and thus holds 180-day exclusivity on this strength, the company said in a statement.
According to IQVIA data, Tofacitinib extended-release tablets had annual sales of around USD 2,082 million in the US for the year ending June 2021.
Zydus said it would produce the drug at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The Zydus group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in 2003-04, it added.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Why not detect sex of foetus, then protect girl child: IMA chief Asokan
Include 4 hrs of physical activity, 8 hrs sleep in routine for optimal health, suggests study
Traffic noise can increase risk of cardiovascular disease: Study
Nearsightedness is at epidemic levels – and the problem begins in childhood
Study finds genetic basis for link between depression, heart disease
MUST WATCH
Latest Additions
LS polls: In SP bastion Mainpuri, it’s ‘Modi ki guarantee’ vs Mulayam’s legacy
Chinese scientist who published Covid-19 virus sequence back in his lab
Bomb threat appears to be hoax; no need to panic: MHA
Harvey Weinstein to face new trial after NY rape conviction overturned
‘BJP put lives at stake…’, claims Akhilesh amid Covishield side-effect row